Biovica International
19.11.2021 16:17:02 CET | ACCESS Newswire | Press release
UPPSALA, SE / ACCESSWIRE / November 19, 2021 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II)
Biovica, active in cancer diagnostics, today announced that results from three different studies using DiviTum®TKa, including a budget impact model, will be presented at the world's largest breast cancer symposium, San Antonio Breast Cancer Symposium (SABCS), in early December. The studies are of a next generation CDK inhibitor, samuraciclib from Carrick Therapeutics, the biomarker study PROMISE performed at the Mayo Clinic, and the DiviTum®TKa budget impact model. All studies focused on the role of DiviTum®TKa in monitoring treatment in women with metastatic breast cancer.
Biovica and Carrick Therapeutics have collaborated on generating TK activity (TKa) data in the phase 1/2A study of samuraciclib (NCT033638939), a first-in-class, oral, selective inhibitor of CDK7 that recently received fast track designation from the US Food and Drug Administration (FDA). The study demonstrates the potential association of TKa levels with treatment effect for this next generation CDK inhibitor.
P1-18-10 A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)
DiviTum®TKa results from the clinical study PROMISE (NCT03281902) conducted at the Mayo Clinic show the association of TKa with progression free survival. The study results are a continuation of the results presented on SABCS 2020. Since then, the study has continued and samples from almost twice as many patients have been tested for TKa, with the new results confirming the initial analysis and earlier DiviTum®TKa results - i.e., the usage of DiviTum®TKa as a valuable tool in the evaluation of treatment effect in metastatic breast cancer.
P5-13-22 Serum thymidine kinase 1 activity (TKa) levels and progression-free survival (PFS) in patients (pts) with hormone receptor positive (HR+) HER2-negative metastatic breast cancer (MBC) on palbociclib (Pb) and endocrine therapy (ET)
Additional results of the healthcare DiviTum®TKa Budget Impact Model show the potential for DiviTum®TKa to substantially reduce the number of CT scans and bone scans used in monitoring women with metastatic breast cancer. As these scans are both costly and a burden on patients, this reinforces the potential benefit of DiviTum®TKa to healthcare systems and to patients. Additionally, the test may enable early identification when a treatment is not effective and therefore enable overall savings of three times the added spend on the DiviTum®TKa test.
P3-03-05 The budget impact of the DiviTum®TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer
"The data on DiviTum®TKa being presented at SABCS strengthens the scientific and economic foundation for the role of the test in the care of breast cancer patients. We are very pleased with these results," said Anders Rylander, CEO of Biovica.
The San Antonio Breast Cancer Symposium, SABCS, runs December 7-10, 2021.
Contact:
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.
Attachments
Biovica's DiviTum®TKa in three studies at SABCS 2021
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/673809/Biovicas-DiviTumRTKa-in-Three-Studies-at-SABCS-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Global Study: Nursing Shortages Require Workforce Policy Solutions, Not Recruitment Campaigns Alone9.9.2026 15:01:00 CEST | Press release
Why people choose nursing, and why they leave, comes down to the same factors PHILADELPHIA, PA / ACCESS Newswire / September 9, 2026 / The global nursing shortage cannot be solved simply by encouraging more people to enter the profession, according to a new evidence brief from the Global Nursing Workforce Centre (GNWC), a joint initiative of the International Council of Nurses (ICN) and TruMerit®. Drawing on research from 42 countries, the brief, The Attractiveness of Nursing for Prospective and Current Nursing Students, finds that the factors influencing people to choose nursing are often the same ones that determine whether they stay. Working conditions, compensation, professional respect, career development opportunities, workplace experiences, and the ability to provide quality care all shape nursing attractiveness to current nurses as well as potential recruits. The findings suggest that countries seeking to strengthen their nursing workforce must focus not only on recruitment, bu
Leggett Dynamics Showcases Award-Finalist Innovations at Automotive News Congress in Detroit9.9.2026 13:00:00 CEST | Press release
Mid-Class Massage System & Smart Brushless Motor Named Finalist For 2026 Automotive News PACE & PACE Pilot Awards DETROIT, MI / ACCESS Newswire / September 9, 2026 / Leggett Dynamics will showcase two next-generation comfort and motion technologies at the 50th Automotive News Congress, September 29-30 in Detroit, Michigan. Both innovations have been named finalists for 2026 Automotive News awards, recognizing the company's commitment to developing innovative comfort and motion solutions that address the evolving needs of automakers and consumers. Leggett Dynamics' Mid-Class Massage System has been named a finalist for the 2026 Automotive News PACE Award, while the company's Smart Brushless Motor has been named a finalist for the 2026 Automotive News PACE Pilot Award. During the 50th Automotive News Congress event, attendees are invited to visit Leggett Dynamics' showcase to explore both technologies firsthand and connect with the team behind their development. The showcase will offer a
IXOPAY Launches Agentic Suite to Help Merchants Support Agentic Commerce and Automate Payment Workflows9.9.2026 12:00:00 CEST | Press release
Flexible, Protocol-Agnostic Suite Helps Merchants Support Agentic Commerce, Preserve Transaction Context and Accelerate Payment Workflows With Secure AI Access DALLAS, TX / ACCESS Newswire / September 9, 2026 / IXOPAY, a leader in payment infrastructure enabling fluid commerce, today announced the launch of the IXOPAY Agentic Suite, a flexible set of tools designed to help merchants prepare for both new agentic buying experiences and the growing role of AI in payment operations. The suite includes Payment Agent, which provides protocol-agnostic connectivity between agentic shopping experiences and existing payment infrastructure; Universal Tokens to preserve transaction context so merchants can confidently participate in agentic commerce while reducing risk; and Model Context Protocol (MCP) Server, which gives approved AI assistants secure and governed access to payment and tokenization capabilities. Together, the suite gives merchants a faster and more flexible way to launch new buyin
Learnis: A New International Network for Transformative Education is Born.8.9.2026 23:05:00 CEST | Press release
Three groups of companies from Italy, Spain and the United States unite in a new corporate network structure, strong of a 20-year shared method that converges under one masterbrand - Learnis, Your transformative education. MILAN, IT / ACCESS Newswire / September 8, 2026 / A new corporate structure brings together Genio Net, the Italian business network directed by Massimo De Donno; Crecimiento Personal SL, the company headed by Giacomo Navone as the franchisor of the Spanish network; and Genius in 21 Days LLC, founded in the United States by Stephanie Turconi and Cosimo Intermite. Across the three countries, the group runs more than 50 learning centers, working with certified instructors and tutors, and reaching over 5,000 participants each year with its immersive courses, training paths and publications, with a focus on personalized study methods and learning. The group has chosen to introduce itself publicly on September 8, 2026, the International Literacy Day. Promoted by UNESCO to
TripGift Launches Its Next-Generation Global Travel Value Platform8.9.2026 14:30:00 CEST | Press release
The 103-currency platform brings together global travel gift cards, rewards, incentives, programmable promotional vouchers and travel redemption across more than 180 countries. NEW YORK CITY, NY / ACCESS Newswire / September 8, 2026 / TripGift, the multi-award-winning global Travel Value Platform, today announced the launch of its next-generation platform, expanding how organizations can integrate travel value into customer, partner and employee programs. Building on TripGift's established global travel gifting and redemption capabilities, the platform brings together its eight proprietary travel gift brands, Travel Value API, Purpose-Bound Promotional Vouchers and travel redemption platform. TripGift's market-leading platform enables travel gift cards to be purchased in 103 currencies and redeemed across more than 180 countries, with access to 2.9 million+ travel and lifestyle booking options, including 2.8 million accommodations, 600 airlines, 30,000 mobility locations, 50,000 tours
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom